domains / families / science / myeloma-mrd-agent

myeloma-mrd-agent

separate

AI-powered minimal residual disease (MRD) analysis for multiple myeloma using next-generation flow cytometry, NGS, and mass spectrometry approaches.

When to use

• When assessing MRD status in multiple myeloma patients post-treatment.
• To select optimal MRD testing modality (NGF vs NGS vs MS).
• For predicting progression-free survival based on MRD kinetics.
• When integrating MRD with other response criteria (IMWG).
• To guide treatment intensification or de-escalation decisions.

Skill page

Source